CD206+巨噬细胞:实验性肺纤维化的无创影像生物标志物与治疗靶点
该研究在博来霉素诱导的小鼠肺纤维化模型中,结合流式细胞术、单细胞RNA测序和99mTc-tilmanocept SPECT分子影像监测CD206+肺巨噬细胞,并评估JAK抑制剂托法替尼抑制M2极化的抗纤维化效果。结果显示CD206靶向SPECT成像可准确检测并量化实验性纤维化早晚期及IPF患者肺活检中CD206+巨噬细胞的增加,并特异性地检测尼达尼布和托法替尼治疗后CD206+肺巨噬细胞的减少。早期CD206+巨噬细胞活体成像可预测实验性肺纤维化进展及尼达尼布和托法替尼的疗效。
要点
- CD206靶向99mTc-tilmanocept SPECT成像可无创检测和量化肺纤维化中CD206+巨噬细胞。
- 早期CD206+巨噬细胞成像可预测实验性肺纤维化进展及尼达尼布、托法替尼疗效。
- M2巨噬细胞可能是进展性肺纤维化患者个体化医学的诊疗靶点。
核心结论
- CD206+ M2巨噬细胞可能是进展性肺纤维化患者个体化医学的相关诊疗靶点。
- CD206靶向活体SPECT成像可准确检测和量化实验性肺纤维化及IPF患者肺活检中的CD206+巨噬细胞。
研究设计与样本
- 研究在博来霉素诱导的小鼠肺纤维化模型中监测CD206+肺巨噬细胞,结合流式细胞术、单细胞RNA测序和99mTc-tilmanocept SPECT分子影像。
- 研究在体内评估了JAK抑制剂托法替尼抑制M2巨噬细胞极化的抗纤维化效果。
主要发现
- 99mTc-tilmanocept靶向SPECT成像可检测并量化实验性纤维化从早期到晚期CD206+巨噬细胞的增加,并在IPF患者肺活检离体中检测到该增加。
- CD206靶向成像可特异性检测尼达尼布和托法替尼治疗后CD206+肺巨噬细胞的减少。
- 早期CD206+巨噬细胞活体成像可预测实验性肺纤维化进展以及尼达尼布和托法替尼的疗效。
临床怎么用
- CD206靶向SPECT成像有望作为无创影像生物标志物用于监测肺纤维化进展和评估尼达尼布、托法替尼等治疗反应。
- M2巨噬细胞极化可能作为进展性肺纤维化的治疗靶点,托法替尼抑制M2极化在实验中显示抗纤维化效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung diseases (ILDs) include a large number of diseases associated with progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF). Despite the rarity of each of the fibrotic ILDs individually, they cumulatively affect a considerable number of patients. PPF is characterised by an excessive collagen deposition leading to functional decline. OBJECTIVES: Therapeutic options are limited to nintedanib and pirfenidone which are only able to reduce fibrosis progression. CD206-expressing M2 macrophages are involved in fibrosis progression, and whether they may be relevant therapeutic targets or biomarkers remains an open question. RESULTS: In our study, CD206+ lung macrophages were monitored in bleomycin-induced lung fibrosis in mice by combining flow cytometry, scRNAseq and in vivo molecular imaging using a single photon emission computed tomography (SPECT) radiopharmaceutical, 99mTc-tilmanocept. The antifibrotic effect of the inhibition of M2 macrophage polarisation with a JAK inhibitor, tofacitinib, was assessed in vivo. We demonstrate that CD206-targeted in vivo SPECT imaging with 99mTc-tilmanocept was able to accurately detect and quantify the increase in CD206+ macrophages from early to advanced stages of experimental fibrosis and ex vivo in lung biopsies from patients with IPF. CD206-targeted imaging also specifically detected a decrease in CD206+ lung macrophages on nintedanib and tofacitinib treatment. Importantly, early in vivo imaging of CD206+ macrophages allowed the prediction of experimental lung fibrosis progression as well as nintedanib and tofacitinib efficacy. CONCLUSIONS: These findings indicate that M2 macrophages may be relevant theranostic targets for personalised medicine for patients with PPF.
引用
- Pommerolle L, Beltramo G, Biziorek L, et al. CD206+ macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis. Thorax. 2024. PMID: 39033028. doi:10.1136/thorax-2023-221168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。